Denali Therapeutics Inc.

About Denali Therapeutics Inc.

Denali Therapeutics is dedicated to defeating neurodegenerative and lysosomal storage diseases through rigorous therapeutic discovery and development, addressing some of the largest medical challenges of our time by leveraging recent scientific insights into genetic causes and biological processes.

Products & Services

Pipeline Programs:A portfolio of programs at various stages of clinical and preclinical development targeting neurodegenerative diseases and addressing causes or risk factors, with expertise in the blood-brain barrier.

Therapeutics for Specific Diseases:Focused on developing medicines for Alzheimer’s disease, Parkinson’s disease, ALS, Hunter Syndrome (MPS II), Sanfilippo Syndrome (MPS III A), and Frontotemporal Dementia (FTD).

Denali Transport Vehicle (TV) Technology: DNL310 (ETV:IDS):A specific therapeutic technology under development, with interim data from Phase 1/2 Cohort A for Hunter Syndrome patients.

Specialties

Neurodegenerative Diseases Lysosomal Storage Diseases Blood-Brain Barrier Biology Therapeutic Discovery and Development Genetics and Pathology of Neurodegeneration Biomarker-Driven Development

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Royalty Financing T: - FT: Royalty Financing	A: 275000000 MR: - FA: $275 million FAN: 275000000	D: 2025-12-04 FD: 2025-12-04	1 investors
2	RT: Royalty Funding T: - FT: Royalty Funding	A: 275000000 MR: - FA: $275 million FAN: 275000000	D: 2025-12-04 FD: 2025-12-04	1 investors
3	RT: PIPE T: - FT: PIPE	A: 500000000 MR: - FA: $500 million FAN: 500000000	D: 2024-02-27 FD: 2024-02-27	3 investors

Royalty Financing Latest

2025-12-04

$275.0M

1 investor (Pro only)

Royalty Funding 2025-12-04

$275.0M

PIPE 2024-02-27

$500.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Ryan Watts

Chief Executive Officer

A

Alexander Schuth

Chief Operating and Financial Officer

C

Carole Ho

Chief Medical Officer

D

Dana Andersen

Chief Technical and Manufacturing Officer

C

Cindy Dunkle

Chief People Officer

J

Joe Lewcock

Chief Scientific Officer

View 18 more team members with Pro

Unlock Full Team Directory

Recent News